Back to search results

Study of [14C]-MRM-3379 in Healthy Men

This study is looking for healthy men aged 18 to 55 to understand how the drug [14C]-MRM-3379 is absorbed, distributed, metabolized, and eliminated from the body after a single oral dose. Researchers will measure the total amount of the drug found in your urine and stool, and how much of the drug and its breakdown products (metabolites) are in your blood over 11 days. This helps them learn about the drug's journey through the body. To join, you must be a healthy male between 18 and 55 years old, with a body mass index (BMI) between 18.0 and 32.0 kg/m2, and weigh between 50 and 110 kg. The study is currently unclear about its recruitment status.

Study design
This is a Phase 1, open-label study involving 8 healthy male participants. It is designed to understand how the drug works in the body.
What's involved
You would take a single oral capsule of [14C]-MRM-3379 on Day 1. Researchers will then collect urine and stool samples, and blood samples for up to 11 days after you take the dose.
Compensation
Not stated in the trial record.
Follow-up
You will be followed for up to 11 days after receiving the dose to measure drug levels and recovery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07712718

A Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of [14C]-MRM-3379

Recruiting
PHASE1Ages 18–55InterventionalBasic science
Mirum Pharmaceuticals, Inc.
~8 participants
Updated 2026-07-17 on ClinicalTrials.gov
What's tested:[14C]-MRM-3379

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Total radioactivity recovery of MRM-3379 in urine and feces
Measured over Up to 11 days post dose
+9 more outcomes measured

Conditions

Healthy Volunteers

Explore related trials

Healthy Volunteers

NCT07712718

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Fortrea Clinical Research Unit Inc

    Madison, Wisconsinstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Kimberly Cruz, MD · PRINCIPAL_INVESTIGATOR · Fortrea Clinical Research Unit Inc.

Who to contact

Clinical Trials Mirum
[email protected]
+16506674085
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Total radioactivity recovery of MRM-3379 in urine and fecesUp to 11 days post dose

    Evaluate the cumulative and total radioactivity in urine and feces following administration of a single oral dose of radiolabeled MRM-3379.

  • Maximum observed concentration (Cmax) of MRM-3379 and 2 metabolites in plasmaUp to 11 days post dose
  • Time to maximum observed concentration (tmax) of MRM-3379 and 2 metabolites in plasmaup to 11 days post dose
  • Area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-tlast) of MRM-3379 and 2 metabolites in plasmaup to 11 days post dose
  • Maximum observed concentration (Cmax) of total radioactivity in plasma and whole bloodup to 11 days post dose
  • Time to maximum observed concentration (tmax) of total radioactivity in plasma and whole bloodup to 11 days post dose
  • Area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-tlast) of total radioactivity in plasma and whole bloodUp to 11 days post dose
  • Amount of MRM-3379 and 2 metabolites excreted in the urine (Ae) over sampling periodUp to 11 days post dose
  • Fraction of MRM-3379 and 2 metabolites excreted in the urine (Fe) as Ae/doseUp to 11 days post dose
  • Renal clearance of MRM-3379 as Ae/AUCUp to 11 days post dose